61186372NSC2012 Copernicus: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) - (Cohort 2 closed to enrollment 09-May-2025)

Objective

Clinical Trial Details

Principal Investigator(s)

Benjamin Solomon, MD

Clinical Trial Categories

• Cancer
• Lung Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org